Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Inqovi (decitabine/cedazuridine)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Otsuka

Drug class:

DNMT inhibitor, Cytidine deaminase inhibitor

Related drugs:

‹

decitabine (40)

azacitidine oral (7)

decitabine (40)

azacitidine oral (7)

›

No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
No biomarker	Chronic Myelomonocytic Leukemia	No biomarker	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1	decitabine/cedazuridine Sensitive: A1 - Approval decitabine / cedazuridine Sensitive : A1
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B
TP53 mutation	Chronic Myelomonocytic Leukemia	TP53 mutation	Chronic Myelomonocytic Leukemia	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B	decitabine/cedazuridine Resistant: B - Late Trials decitabine / cedazuridine Resistant : B
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	decitabine/cedazuridine Sensitive: C3 – Early Trials decitabine / cedazuridine Sensitive : C3	decitabine/cedazuridine Sensitive: C3 – Early Trials decitabine / cedazuridine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3
ASXL1 mutation	Acute Myelogenous Leukemia	ASXL1 mutation	Acute Myelogenous Leukemia	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3	venetoclax + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + decitabine / cedazuridine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3	venetoclax + enasidenib + decitabine/cedazuridine Sensitive: C3 – Early Trials venetoclax + enasidenib + decitabine / cedazuridine Sensitive : C3